Related references
Note: Only part of the references are listed.Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine
Angeline Oi-Shan Lo et al.
ANTIVIRAL THERAPY (2013)
Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily
Nghiem B. Ha et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
Teerha Piratvisuth et al.
PLOS ONE (2013)
A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine
Jeong Heo et al.
ANTIVIRAL THERAPY (2012)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2012)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2012)
The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir
E. Sheen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
E. Jenny Heathcote et al.
GASTROENTEROLOGY (2011)
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
Yanni Yan-Ni Lui et al.
ANTIVIRAL THERAPY (2010)
Management of chronic hepatitis B: experience from China
J. Sun et al.
JOURNAL OF VIRAL HEPATITIS (2010)
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
Yun-Fan Liaw et al.
GASTROENTEROLOGY (2009)
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen-Positive Patients with Chronic Hepatitis B: A Randomized International Study of Entecavir Versus Adefovir
Nancy Leung et al.
HEPATOLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy
Jurrien G. P. Reijnders et al.
JOURNAL OF HEPATOLOGY (2009)
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B
Maria Buti et al.
JOURNAL OF HEPATOLOGY (2009)
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
Stefan Zeuzem et al.
JOURNAL OF HEPATOLOGY (2009)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial
Jinlin Hou et al.
HEPATOLOGY (2008)
Telbivudine versus lamivudine in patients with chronic hepatitis B
Ching-Lung Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Entecavir therapy for up to 96 weeks in patients with HBeAg-Positive chronic hepatitis B
Robert G. Gish et al.
GASTROENTEROLOGY (2007)
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B
Emmet B. Keeffe et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Share Paper
